Trial Profile

Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Abiraterone acetate/niraparib (Primary) ; Apalutamide (Primary) ; Darolutamide (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Prednisolone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms STAMPEDE2

29 Aug 2025 Planned number of patients changed from 8000 to 3360.
29 Aug 2025 Protocol has been amended to remove two arms (Active Comparator: Arm A(N) of Niraparib Comparison and Experimental: Arm N of Niraparib Comparison), it has been changed from 6 to 4.
29 Aug 2025 Planned End Date changed from 1 Mar 2034 to 1 Mar 2032.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com